Bausch + Lomb (BLCO) Projected to Post Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Wednesday, July 30th. Analysts expect Bausch + Lomb to post earnings of $0.07 per share and revenue of $1.25 billion for the quarter. Bausch + Lomb has set its FY 2025 guidance at EPS.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its earnings results on Wednesday, April 30th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.10). Bausch + Lomb had a negative net margin of 7.50% and a positive return on equity of 2.62%. The company had revenue of $1.15 billion for the quarter, compared to the consensus estimate of $1.15 billion. During the same period in the prior year, the firm posted $0.07 EPS. The business's revenue for the quarter was up 3.5% compared to the same quarter last year. On average, analysts expect Bausch + Lomb to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Bausch + Lomb Trading Up 2.0%

NYSE:BLCO traded up $0.28 during midday trading on Friday, hitting $14.25. 1,755,751 shares of the company traded hands, compared to its average volume of 770,057. The firm's fifty day moving average is $12.59 and its 200-day moving average is $14.07. Bausch + Lomb has a 12-month low of $10.45 and a 12-month high of $21.69. The firm has a market capitalization of $5.04 billion, a P/E ratio of -13.84, a P/E/G ratio of 1.60 and a beta of 0.62. The company has a current ratio of 1.56, a quick ratio of 0.96 and a debt-to-equity ratio of 0.74.

Wall Street Analyst Weigh In

BLCO has been the topic of a number of recent analyst reports. Citigroup increased their target price on Bausch + Lomb from $13.00 to $15.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 9th. Barclays dropped their price target on Bausch + Lomb from $19.00 to $16.00 and set an "equal weight" rating on the stock in a research report on Monday, June 9th. Evercore ISI increased their price target on Bausch + Lomb from $15.50 to $16.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 8th. Needham & Company LLC reissued a "hold" rating on shares of Bausch + Lomb in a research report on Thursday, April 24th. Finally, Royal Bank Of Canada dropped their price target on Bausch + Lomb from $18.00 to $17.00 and set an "outperform" rating on the stock in a research report on Friday, April 4th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $15.45.

Insider Activity

In other news, CEO Brent L. Saunders purchased 22,000 shares of the stock in a transaction dated Thursday, May 22nd. The shares were purchased at an average cost of $11.28 per share, with a total value of $248,160.00. Following the completion of the purchase, the chief executive officer directly owned 719,156 shares of the company's stock, valued at approximately $8,112,079.68. The trade was a 3.16% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.76% of the stock is owned by corporate insiders.

Institutional Trading of Bausch + Lomb

An institutional investor recently raised its position in Bausch + Lomb stock. Goldman Sachs Group Inc. raised its stake in Bausch + Lomb Corporation (NYSE:BLCO - Free Report) by 428.7% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 299,671 shares of the company's stock after buying an additional 242,993 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.08% of Bausch + Lomb worth $4,345,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.07% of the company's stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.